Protocol Ledger

NCT06365216 · Phase II · ACTIVE NOT RECRUITING

ALS Phase II Study of NX210c

Interventional Phase II clinical trial protocol NCT06365216 sponsored by Axoltis Pharma in Neurology, Psychiatry, and Pain, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2024-10-25 Enrollment: 80 participants (ESTIMATED) Federal Source: clinicaltrials.gov/study/NCT06365216
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)80 participants (ESTIMATED)
Disclosed U.S. Hospital Campuses vs Median (6 sites)0 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT06365216
Protocol FieldVerified Registry Value
NCT IdentifierNCT06365216
Consolidated Lead SponsorAxoltis Pharma
Therapeutic Condition CohortNeurology, Psychiatry, and Pain
Clinical Trial PhasePhase II
Overall Recruitment StatusACTIVE NOT RECRUITING
Registered Enrollment80 participants (ESTIMATED)
Registered Start Date2024-10-25
WhyStopped ClassificationNot Stopped

Search related sites and sponsors in the Interactive Directory, explore Neurology, Psychiatry, and Pain Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI